Table 1.
Patient, disease, and transplantation characteristics based on number of HLA-DPB1 mismatches
| Variable | 10/12 | 11/12 | 12/12 | Total |
|---|---|---|---|---|
| (N=65) | (N=172) | (N=73) | (N=310) | |
| Diagnosis at transplant | ||||
| AML | 35 (54%) | 47 (27%) | 30(41%) | 112 (36%) |
| Lymphoproliferative discordes | 12 (18%) | 55 (32%) | 17 (23%) | 84 (27%) |
| MDS/MPN/CMML | 12 (18%) | 39 (23%) | 23 (32%) | 74 (24%) |
| ALL | 4 (6%) | 9 (5%) | 3 (4%) | 16 (5%) |
| Non-malignant | 2 (3%) | 14 (8%) | 0 | 16 (5%) |
| Leukemia | 0 | 6 (3%) | 0 | 6 (2%) |
| Other | 0 | 2 (1%) | 0 | 2 (1%) |
| Disease risk | ||||
| Low | 26 (40%) | 57 (33%) | 25 (34%) | 108 (35%) |
| Intermediate | 8 (12%) | 21 (12%) | 9 (12%) | 38 (12%) |
| High | 26 (40%) | 65 (38%) | 32 (44%) | 123 (40%) |
| Non-Malignant | 5 (8%) | 23 (13%) | 7 (10%) | 35 (11%) |
| Other | 0 | 6 (3%) | 0 | 6 (2%) |
| Gender | ||||
| Female | 29 (45%) | 70 (41%) | 32 (44%) | 131 (42%) |
| Male | 36 (55%) | 102 (59%) | 41 (56%) | 179 (58%) |
| Female donor, male recipient | ||||
| Yes | 10 (15%) | 20 (12%) | 10 (14%) | 40 (13%) |
| No | 55 (85%) | 152 (88%) | 63 (86%) | 270 (87%) |
| CMV status(recipient/donor) | ||||
| −/− | 12 (19%) | 21 (12%) | 7 (10%) | 40 (13%) |
| −/+ | 6 (9%) | 19 (11%) | 5 (7%) | 30 (9%) |
| +/− | 26 (40%) | 88 (51%) | 37 (50%) | 151 (49%) |
| +/+ | 21 (32%) | 44 (26%) | 24 (33%) | 89 (29%) |
| Patient age (median, range) | 58 (3-71) | 57 (2-72) | 59 (5-73) | 58 (2-73) |
| <58 | 31 (48) | 89 (52) | 34 (47) | 154 (50) |
| ≥58 | 34 (52) | 83 (48) | 39 (53) | 156 (50) |
| Donor age (median, range) | 31 (20-52) | 31 (19-57) | 28 (18-55) | 30 (18-57) |
| <30 | 27 (42) | 78 (46) | 39 (53) | 144 (47) |
| ≥30 | 38 (58) | 93 (54) | 34 (47) | 165 (53) |
| Graft source | ||||
| Bone marrow | 5 (8%) | 21 (12%) | 9 (12%) | 35 (11%) |
| Peripheral blood stem cells | 60 (92%) | 151 (88%) | 64 (88%) | 275 (89%) |
| GvHD prophylaxis | ||||
| Tacro/Siro based | 60 (92%) | 158 (92%) | 71 (97%) | 289 (93%) |
| Other | 5 (8%) | 14 (8%) | 2 (3%) | 21 (7%) |
| Conditioning regimen* | ||||
| Fludarabine/Melphalan based | 57 (88%) | 155 (90%) | 64 (88%) | 276 (89%) |
| Fludarabine/Cyclophosphamide based | 2 (3%) | 11 (6%) | 3 (4%) | 16 (5%) |
| Clofarabine/Melphalan based | 5 (8%) | 6 (3%) | 6 (8%) | 17 (5%) |
| Fludarabine/TBI | 1 (2%) | 0 | 0 | 1 (1%) |
| KPS | ||||
| ≤80 | 11 (17%) | 33 (19%) | 22 (30%) | 66 (22%) |
| 90+ | 37 (57%) | 106 (62%) | 38 (52%) | 181 (58%) |
| Unknown | 17 (26%) | 33 (19%) | 13 (18%) | 63 (20%) |
| Comorbidity – HCT CI | ||||
| 0 | 22 (34%) | 80 (47%) | 28 (38%) | 130 (42%) |
| 1 | 11 (17%) | 23 (13%) | 9 (12%) | 43 (14%) |
| 2 | 3 (5%) | 5 (3%) | 6 (8%) | 14 (5%) |
| ≥3 | 10 (15%) | 30 (17%) | 17 (23%) | 57 (18%) |
| Unknown | 19 (29%) | 34 (20%) | 13 (18%) | 66 (21%) |
AML: Acute Myeloid Leukemia; Lymphoproliferative Disorders includes: Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Multiple Myeloma and Chronic Lymphocytic Leukemia; MDS/MPN/CMMoL: Myelodysplastic Syndrome/Myeloproliferative Neoplasms/Chronic Myelomonocytic Leukemia; ALL: Acute Lymphocytic Leukemia; Non-Malignant includes: Aplastic Anemia, Sickle Cell Disease, and Thalassemia; Other Leukemia includes: Acute Biophenotypic Leukemia, Leukemia, general, Chronic Myeloid Leukemia, Histiocytic Syndrome, and Other Hematopoietic; Other includes: Other and Kidney, Renal Cell; TBI: Total Body Irradiation; KPS: Karnofsky Performance Status; HCT CI: Hematopoietic Cell Transplant Specific Co-morbidity Index.
Main conditioning regimen consisted of Fludarabine (25 mg/m2 for 5 days) with Melphalan (100 or 140 mg/m2)-based regimen was the main condition regimen in our cohort.